PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Linzagolix→

Linzagolix PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
935283-04-8
Molecular formula
C22H15F3N2O7S
Molecular weight
508.4 g/mol
Drug class
Non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonistanti-gonadotropin
Mechanism of action
Competitively binds pituitary GnRH receptors and inhibits endogenous GnRH signalling, reducing LH and FSH secretion and producing dose-dependent suppression of ovarian oestradiol and progesterone.
Indications / reported uses
  • Treatment of moderate-to-severe symptoms associated with uterine fibroids in adult women of reproductive age, under the applicable product authorisation.
  • Treatment of endometriosis-associated symptoms where authorised by the relevant product label.

Sources: https://www.medicines.org.uk/emc/product/100020/smpc · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/linzagolix

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Linzagolix PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Linzagolix Permitted Daily Exposure (PDE) report (the Linzagolix PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Linzagolix Occupational Exposure Limit (OEL) report (the Linzagolix OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.